Raising $1B Series A at $5B valuation. Sam Altman-backed. Largest-funded pure-play longevity startup. First human trial targeting Australia launch.
Retro Biosciences is the largest-funded pure-play longevity company in history, raising $1 billion in Series A financing at a $5 billion valuation with Sam Altman (OpenAI CEO) as a primary backer. The company is pursuing cellular reprogramming, autophagy enhancement, and plasma factor therapeutics in parallel — a multi-pronged approach to extending healthy human lifespan by targeting the cellular hallmarks of aging simultaneously.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.